HK Stock Market Move | KEYMED BIO-B(02162) rose by over 7%, Goldman Sachs said that Sipokiba monoclonal antibody is expected to lay the foundation for the company's valuation.

KEYMED BIO-B (02162) rose by more than 7%, reaching a 7.14% increase as of the time of publication, at 64.55 Hong Kong dollars, with a turnover of 2.81 billion Hong Kong dollars. On the news front, Goldman Sachs released a research report stating a "buy" rating for Connoa, with a target price of 92.67 Hong Kong dollars. The bank pointed out that the company's first commercial product, Stapokibart, has been approved in mainland China for indications of atopic dermatitis, chronic sinusitis, and seasonal allergic rhinitis. With the first-mover advantage in the relevant fields, the bank believes that the drug is expected to lay the foundation for the company's valuation, with peak sales expected to exceed 5 billion RMB by 2035. Additionally, the bank expects greater growth potential from CM512, believing that the drug can become a preferred option for asthma and chronic obstructive pulmonary disease; global sales of CM512 before and after the PoS stage are expected to reach 3.3 billion and 694 million US dollars respectively by 2035. It is reported that Stapokibart (Dupilumab, Kanjuta) had sales of about 169 million yuan in the first half of this year. Huatai's previous research report pointed out that Dupilumab has evident advantages in efficacy and safety in the field of atopic dermatitis, and strong competitiveness. With the exclusive indications in the field of rhinology driving sales growth rapidly, the company plans to participate in the 2025 medical insurance negotiations, which is expected to improve accessibility. At the same time, the company's multiple early pipeline projects have strong global potential, and multiple catalysts are expected to be realized.